CA
Clune & Associates Portfolio holdings
AUM
$400M
1-Year Est. Return
10.98%
1 Year Est. Return
+10.98%
AUM
$365M
AUM Growth
+$39.7M
(+12%)
Holding
157
Top Buys
| 1 | +$1.41M | |
| 2 | +$1.33M | |
| 3 | +$1.17M | |
| 4 |
Dimensional Short-Duration Fixed Income ETF
DFSD
|
+$1.11M |
| 5 |
Dimensional US Small Cap ETF
DFAS
|
+$1.09M |
Top Sells
| 1 | +$1.23M | |
| 2 | +$649K | |
| 3 | +$214K | |
| 4 |
Merck
MRK
|
+$200K |
| 5 |
Dimensional Ultrashort Fixed Income ETF
DUSB
|
+$185K |
Sector Composition
| 1 | Technology | 3.86% |
| 2 | Financials | 3.24% |
| 3 | Healthcare | 1.48% |
| 4 | Industrials | 1.26% |
| 5 | Consumer Discretionary | 1.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
Illinois Tool Works
ITW
$74.9B
| $204K | 0.06% |
827
|
|
||
152
Vanguard FTSE Developed Markets ETF
VEA
$179B
| $202K | 0.06% |
+3,548
|
|
||
153
Vanguard ESG US Stock ETF
ESGV
$11.7B
| $202K | 0.06% |
+1,841
|
|
||
154
iShares MSCI Emerging Markets ex China ETF
EMXC
$13.9B
| $201K | 0.06% |
+3,188
|
|
||
155
Philip Morris
PM
$234B
| $200K | 0.05% |
+1,099
|
|
||
156
Acumen Pharmaceuticals
ABOS
$119M
| $19.1K | 0.01% |
16,500
|
|
||
|
157
Merck
MRK
$218B
| – | – |
-2,230
|
|